Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Monopar Therapeutics Inc (MNPR)

Monopar Therapeutics Inc (MNPR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 510,751
  • Shares Outstanding, K 6,683
  • Annual Sales, $ 0 K
  • Annual Income, $ -15,590 K
  • EBIT $ -22 M
  • EBITDA $ -22 M
  • 60-Month Beta 1.35
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.40

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.55
  • Number of Estimates 6
  • High Estimate -0.45
  • Low Estimate -0.76
  • Prior Year -2.23
  • Growth Rate Est. (year over year) +75.34%

Price Performance

See More
Period Period Low Period High Performance
1-Month
72.00 +11.94%
on 10/22/25
89.86 -10.30%
on 10/30/25
+0.47 (+0.59%)
since 10/17/25
3-Month
29.18 +176.22%
on 08/26/25
105.00 -23.24%
on 10/06/25
+46.34 (+135.26%)
since 08/18/25
52-Week
18.32 +339.96%
on 11/19/24
105.00 -23.24%
on 10/06/25
+62.15 (+336.86%)
since 11/18/24

Most Recent Stories

More News
Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments

WILMETTE, Ill., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments...

MNPR : 80.60 (+5.46%)
Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025

WILMETTE, Ill., Nov. 09, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments...

MNPR : 80.60 (+5.46%)
Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025

WILMETTE, Ill., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments...

MNPR : 80.60 (+5.46%)
Monopar Therapeutics Inc (MNPR) Receives a Buy from Cantor Fitzgerald

Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on Monopar Therapeutics Inc yesterday and set a price target of $109.00. The company’s shares closed yesterday at $98.57.Elevate Your...

MNPR : 80.60 (+5.46%)
Raymond James Sticks to Its Buy Rating for Monopar Therapeutics Inc (MNPR)

In a report released today, Christopher Raymond from Raymond James maintained a Buy rating on Monopar Therapeutics Inc, with a price target of $142.00. The company’s shares closed last Friday at $99.39.Elevate...

MNPR : 80.60 (+5.46%)
Oppenheimer Sticks to Their Buy Rating for Monopar Therapeutics Inc (MNPR)

Oppenheimer analyst Andreas Argyrides maintained a Buy rating on Monopar Therapeutics Inc today and set a price target of $115.00. The company’s shares closed yesterday at $84.73.Elevate Your Investing...

MNPR : 80.60 (+5.46%)
Analysts’ Top Healthcare Picks: Maze Therapeutics, Inc. (MAZE), Repligen (RGEN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Maze Therapeutics, Inc. (MAZE – Research Report), Repligen (RGEN – Research Report) and Monopar Therapeutics...

MNPR : 80.60 (+5.46%)
RGEN : 153.06 (+2.72%)
MAZE : 33.23 (-0.89%)
Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

WILMETTE, Ill., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics”, “Monopar”, or the “Company”), a clinical-stage biopharmaceutical company...

MNPR : 80.60 (+5.46%)
Monopar Announces Journal of Hepatology Publishes Physicians’ Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients

WILMETTE, Ill., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments...

MNPR : 80.60 (+5.46%)
Small Caps Shine Following Fed’s First Rate Cut in 9 Months

The Federal Reserve delivered its first rate cut in nine months, and small-cap stocks wasted no time celebrating. While the S&P 500 (SPX) dipped modestly and the Russell 3000 Index (RUA) closed near even,...

IPM : 1.8600 (-1.59%)
MNPR : 80.60 (+5.46%)
SPRC : 2.42 (-2.02%)
BGM : 8.90 (-2.20%)
BLDP : 2.89 (-0.69%)
IWV : 373.93 (-0.71%)
SQFT : 4.64 (+0.22%)
APLM : 18.34 (-14.50%)
GV : 1.3200 (+9.09%)
TVRD : 4.12 (+2.23%)
THH : 8.40 (-2.33%)
WFC : 83.86 (+0.53%)

Business Summary

Monopar Therapeutics Inc. is a biopharmaceutical company. It is focused on developing drugs for cancer patients. The company's intellectual property pipeline consists of Validive(R), Camsirubicin (MNPR-201) and MNPR-101 which are in clinical stage. Monopar Therapeutics Inc. is based in Wilmette, United...

See More

Key Turning Points

3rd Resistance Point 92.81
2nd Resistance Point 87.96
1st Resistance Point 84.28
Last Price 80.60
1st Support Level 75.75
2nd Support Level 70.90
3rd Support Level 67.22

See More

52-Week High 105.00
Last Price 80.60
Fibonacci 61.8% 71.89
Fibonacci 50% 61.66
Fibonacci 38.2% 51.43
52-Week Low 18.32

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar